Concepedia

Author

Hiroomi Tada

The University of Texas MD Anderson Cancer Center

Also Known As

Hiroomi Tada

21

Publications

1.2K

Citations

10

H-Index

38

Concepts

All Affiliations

The University of Texas MD Anderson Cancer CenterGlaxoSmithKline (Netherlands)University of Pennsylvania
HT

About

Hiroomi Tada is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and pathology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

7

7

1K

2

Health Sciences

1

1

417

3

Cell Biology

1

1

163

4

Immunology

1

1

163

5

Microbiology

1

1

91

Hiroomi Tada

×

10

Publications

1.2K

Citations

10

H-Index

YearCitations

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

Roy S. Herbst, Yan Sun, Wilfried Eberhardt,

The Lancet Oncology

2010

417

Pigmented epithelioid melanocytoma

Jon R. Ward, Stephen Brady, Hiroomi Tada,

International Journal of Dermatology

2006

206

KOC (K Homology Domain Containing Protein Overexpressed in Cancer)

Rhonda K. Yantiss, Bruce A. Woda, Gary R. Fanger,

The American Journal of Surgical Pathology

2005

163

Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors

Antoinette R. Tan, Darlene Gibbon, Mark N. Stein,

Cancer Chemotherapy and Pharmacology

2013

105

<i>HLA-B</i> *57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer

Chun‐Fang Xu, Toby Johnson, Xiaojing Wang,

Clinical Cancer Research

2015

95

The entire nucleotide sequence of the genome of human hepatitis A virus (isolate MBB)

Aniko V. Paul, Hiroomi Tada, K. von der Helm,

Virus Research

1987

91

Systemic IFN-β gene therapy results in long-term survival in mice with established colorectal liver metastases

Hiroomi Tada, David J. Maron, Eugene A. Choi,

Journal of Clinical Investigation

2001

47

Comprehensive genomic profiling in FIGHT-202 reveals the landscape of actionable alterations in advanced cholangiocarcinoma.

Ian M. Silverman, Karthikeyan Murugesan, Christine Lihou,

Journal of Clinical Oncology

2019

43

Intra-arterial Delivery of a Recombinant Adenovirus Does Not Increase Gene Transfer to Tumor Cells in a Rat Model of Metastatic Colorectal Carcinoma

David J. Maron, Hiroomi Tada, Albert D. Moscioni,

Molecular Therapy

2001

19

Ex Vivo Drug Sensitivity Correlates with Clinical Response and Supports Personalized Therapy in Pediatric AML

Debbie Strachan, Christine Gu, Ryosuke Kita,

Cancers

2022

10

Page 1